CDMO biologics GMP certified
CDMO services GLP certified
european CDMO company GCP
end-to-end CDMO pharma services ISO

Located in the heart of Europe & EU

Our headquarters is based in central Poland, 1.5 hours’ drive from the Warsaw airport. As one would anticipate from an european CDMO, we guarantee the highest levels of production and analytics standards for your business. Additionally, our “can-do” approach to our clients’ needs offers solutions to unforeseen challenges which we overcome as a team.

Press releases

Mabion’s high cost discipline and intensification of business development activities in 3Q 2024

Learn more

Changes in the composition of Mabion S.A.’s Board of Directors.

Learn more

Mabion’s solid results and balance sheet in Q2’24, first CDMO orders signed and readiness to acquire more

Learn more

Mabion will complete CDMO orders worth about PLN 5.5 million for a new UK client

Learn more

Mabion expands collaboration with Novavax to include analytical work for new product – combined influenza vaccine and COVID

Learn more

Growing pipeline of submitted bids and another period of solid results and operating cash flow for Mabion in Q1 2024

Learn more

Very good results and successful implementation of Mabion Strategy in 2023

Learn more

Nigel Stapleton to support Mabion’s sales growth in role of Business Development Director for Europe

Learn more

Marty Henehan will strengthen Mabion’s sales operations as Vice President of Business Development for North America

Learn more

Mabion presents ESG Strategy for 2024-2027

Learn more

Following a very good period of Q1–Q3, Mabion raises expectations for the full year results in 2023

Learn more

Changes in the composition of the Management Board of Mabion S.A.

Learn more

Third consecutive quarter of very strong results,high profitability and consistent transformation towards CDMO

Learn more

Mabion with agreement to buy new bioreactors, diversifies technology and opens to new customers

Learn more

Mabion with a quarter of record results. Implementation of activities announced in the Strategy

Learn more

Mabion announces Strategy for 2023-2027 and summarizes very good Q4 and full year 2022

Learn more

Mabion expands collaboration with Novavax for vaccine antigen for COVID-19 variant Omicron

Learn more

Mabion with tenth order under Novavax partnership

Learn more

Mabion has received ODD status from the FDA for the drug MabionCD20 in the indication of autoimmune hemolytic anemia

Learn more

Mabion has signed a loan agreement with the EBRD for $15 million (about PLN 66 million)

Learn more

Mabion has secured approval from the FDA to designate MabionCD20 as an orphan drug for the indication of membranous nephropathy

Learn more

Science news

Read what’s happening in the world of biologics CDMO.

Mabion Wins Best of Industry Insights Award for Biologics Outsourcing Article in Outsourced Pharma Best Of 2024

Mabion SMEs’s article has been awarded Best of Industry Insights in the Biologics Outsourcing category of the Outsourced Pharma Best Of 2024 awards.

Learn more

FDA approves first medication for obstructive sleep apnea: Eli Lilly’s GLP-1 agonist

The FDA has approved Eli Lilly’s Zepbound (tirzepatide) as the first-ever medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, providing a pharmacological alternative to CPAP machines and surgery.

Learn more

Biocon’s Yesintek receives EMA and FDA approval as the next ustekinumab biosimilar

Yesintek, a biosimilar to ustekinumab developed by Biocon, has received approval from both the EMA and FDA, joining other ustekinumab biosimilars like Amgen’s Wezlana and Alvotech’s Selarsdi.

Learn more

Lecanemab approved by EMA in early Alzheimer’s after re-evaluation

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Transplantation of stem cell islets cures patient from type 1 diabetes

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Nobel prize in medicine awarded to micro-RNA discoverers

This year’s Nobel prize in physiology or medicine has been awarded to Victor Ambros and Gary Ruvkun who discovered microRNAs (miRNAs) and elucidated their role in regulating gene expression. MicroRNAs are a class of small RNA molecules that reduce the expression of specific genes by binding to and disrupting their corresponding mRNAs. This regulation of gene expression pattern by miRNAs plays a key role in driving cell differentiation and determining cell fate. The discoveries of this year’s Nobel laureates are likely to pave the way for novel cancer therapies.

Learn more

Zolbetuximab demonstrates significant benefit in gastric cancer and receives approval in the EU

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Are mucosal vaccines the future of COVID-19 prevention?

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Lecanemab, a breakthrough Alzheimer’s drug, rejected by EMA

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Huge spike in the use of GLP-1 analogs amid severe shortages

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Recombinant coagulation factor with extended half-life prevents bleeding in children with severe hemophilia A

A genetically engineered factor VIII concentrate with an extended half-life, almost completely prevented spontaneous bleeding among children suffering from hemophilia A. Unlike older FVIII preparations that require infusions every 2 or 3 days, the new drug can be administered once per week.

Learn more

Antibody-drug conjugates continue their victory march

The victory march of antibody-drug conjugates continues unabated. In two recent trials, benlatamab mafodotin was found to delay the progression of pre-treated or relapsed multiple myeloma outperforming the standard therapy.

Learn more

COVID-19 vaccines for 2024/25 season will target JN.1 variant

WHO and EMA published a recommendation to update the composition of COVID-19 vaccines for 2024/25 season to JN.1 variant. In recent months JN.1 has become the most widely circulating variant worldwide. It differs from the XBB variant included in the current season vaccines, causing substantial fall in their effectiveness.

Learn more

First-in-class IL-15 superagonist wins FDA approval

The first-ever superagonist of interleukin-15 (IL-15), with a highly unique structure, has just received FDA approval in the treatment of bladder cancer.

Learn more

Next step to revise pharmaceutical legislation made by EU parliament

European Parliament adopted a comprehensive pharmaceutical reform package to address drug pricing, accessibility, and safety concerns across the EU. Reform measures include enhancing price transparency, strengthening pharmacovigilance efforts, and streamlining regulatory processes to ensure patient access to safe and affordable medications.

Learn more

A biologic drug for diabetes effective in early Parkinson’s disease

Lixisenatide, a popular biologic for type 2 diabetes, was found to delay the progression of Parkinson’s disease in a Phase II clinical trial. However, larger studies are needed to confirm this finding and secure regulatory approval.

Learn more